Chugai reports vamikibart data for Chugai Pharmaceutical stock

Published on 10/14/2026 at 10:54 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Roche data covered 52 weeks of vamikibart in uveitic macular edema. Chugai Pharmaceutical stock trades at EUR 34.04 on October 14, 2026.

Vamikibart data and earnings

Roche reported 52-week vamikibart data in uveitic macular edema on October 13, 2026.
Chugai reported JPY 341.58 billion in second-quarter 2026 revenue, up 17.80 percent year over year.
Chugai Pharmaceutical stock trades at EUR 34.04 at 10:42 a.m. CEST at Lang & Schwarz on October 14, 2026.

Chugai Pharmaceutical, JP3519400000, Illustration mit AI erstellt.

Chugai Pharmaceutical (JP3519400000) was trading at EUR 34.04 at Lang & Schwarz on October 14, 2026, at 10:42 a.m. CEST. On October 13, 2026, Roche reported one-year vamikibart data in uveitic macular edema, giving the stock a fresh clinical-data reference point.

Vamikibart reaches 52 weeks

According to VermögensZentrum on October 13, 2026, Roche said Phase III results showed sustained vision improvements and reduced macular swelling through 52 weeks. About two-thirds of patients who moved to as-needed dosing required no additional treatment, while most patients who did need another injection required one.

The safety profile remained consistent over the one-year period, according to the same dated report. The data connect Chugai's development portfolio with Roche's late-stage ophthalmology work while leaving the commercial outcome dependent on regulatory and clinical progress.

Earnings provide a financial anchor

JPX Market Explorer reported that Chugai's second-quarter 2026 revenue reached JPY 341.58 billion, compared with JPY 290.01 billion a year earlier. Net income was JPY 116.33 billion, versus JPY 97.16 billion in the comparable quarter.

The revenue comparison represents growth of 17.80 percent year over year, while net income increased 19.73 percent. Those figures give investors a measurable financial backdrop for a pipeline story that otherwise depends on future clinical milestones.

What comes next for Chugai?

Chugai's investor-relations calendar lists its fiscal 2026 third-quarter results for October 27, 2026, at 5:00 p.m. Japan Standard Time, followed by a results conference at 6:00 p.m. Japan Standard Time, according to Chugai Pharmaceutical.

Citi maintained a Buy rating and a JPY 11,100.00 price target in a report dated October 7, 2026, as reported by Markets Insider. The target is expressed in yen and is separate from the euro quote at Lang & Schwarz.

Three dated milestones

On January 31, 2026, Chugai reported fiscal 2025 revenue of JPY 1,257.941 billion through JPX Market Explorer. On July 24, 2026, the company reported second-quarter revenue of JPY 341.584 billion through the same source. On October 13, 2026, Roche reported 52-week vamikibart data, according to VermögensZentrum.

Upcoming reporting dates

The next listed event is Chugai's fiscal 2026 third-quarter results on October 27, 2026, at 5:00 p.m. Japan Standard Time, followed by the financial-results conference at 6:00 p.m. Japan Standard Time, according to Chugai Pharmaceutical.

Stock price in Berlin trading

Chugai Pharmaceutical stock was trading at EUR 34.04 at Lang & Schwarz on October 14, 2026, at 10:42 a.m. CEST. The further course of trading is shown by the continuously updated real-time quote of Chugai Pharmaceutical stock.